New Anticoagulation Drugs for Atrial Fibrillation

TS Potpara, Gregory Lip

Research output: Contribution to journalEditorial

7 Citations (Scopus)


Atrial fibrillation (AF) confers an increased risk of ischemic stroke or thromboembolism that is reduced by long-term oral anticoagulant therapy. Until recently, the latter has typically been one from the vitamin K antagonist (VKA) class of drugs. Although highly effective, VKAs have limitations, and their use is challenging for both patients and clinicians. A new generation of oral anticoagulant drugs is emerging, including several drugs that appear to be viable alternatives to VKAs in AF patients.
Original languageEnglish
Pages (from-to)502-506
Number of pages5
JournalClinical Pharmocology and Therapeutics
Issue number4
Publication statusPublished - 1 Oct 2011


Dive into the research topics of 'New Anticoagulation Drugs for Atrial Fibrillation'. Together they form a unique fingerprint.

Cite this